Following lead-in, participants will return to the lab for a baseline visit. At this time, participants will first be informed to which treatment they were randomly assigned by the biostatistician (using a random number generator) and to which they will be asked to adhere for 16 weeks. We will divulge this prior to going any further, to provide an opportunity for participants to withdraw. Willing participants will then undergo a series of measurements: